Saturday 17 October 2026
Export SVA’s income statement to Excel — free account
Sinovac Biotech, Ltd.
Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.
6.47
0.00
0.00%
Follow SVA
| Older periods | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
38.39% | 0.00% | 0.00% | 0.00% | |
Piotroski F-Score |
4 | — | — | — | |
| 26.39% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
29.88% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
18.22 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
4,708.18 | (801.49) | (709.59) | (786.38) | |
Capital Expenditures |
(860.83) | (860.14) | (455.24) | (196.17) | |
| Other line items | |||||
Cash ROIC |
20.02% | (3.58%) | (4.24%) | (6.03%) | |
Accounts Receivable Turnover |
10.59 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
1.48 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
4.44 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
227.99 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
50.84 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.20) | — | — | — | |
Research and Development Expense of Revenue |
6.92% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
14.87% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
1.60 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.29 | 0.08 | 0.14 | 0.23 | |
Capex/Depreciation |
(2.82) | (12.07) | (3.85) | (1.20) | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.09 | 0.00 | 0.00 | 0.00 |
Columns are period end dates